Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

~70 mi. (Grenoble, France, +96 more cities)

Centre Hospitalier Universitaire de Grenoble

Diffuse Large B-Cell Lymphoma, +1 more condition

brentuximab vedotin, +2 more drugs

chemotherapy, +1 more type

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

~70 mi. (Grenoble, France, +87 more cities)

Hopital Albert Michallon

ALK Fusion

Non-Small Cell Lung Carcinoma

brigatinib

targeted therapy

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

~72 mi. (La Tronche, France, +31 more cities)

Centre Hospitalier Universitaire de Grenoble

TNFRSF8 Deficient Expression

Adult T-Cell Leukemia/Lymphoma, +8 more conditions

brentuximab vedotin, +3 more drugs

chemotherapy, +2 more types

Efficacy, Safety, and Tolerability of V937 Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

~72 mi. (La Tronche, France, +25 more cities)

CHU de Grenoble Hopital Nord ( Site 2027)

Melanoma

coxsackievirus A21, +1 more drug

immunotherapy

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

~87 mi. (Valence, France, +137 more cities)

Centre Hospitalier de Valence-Service de Dermatologie ( Site 0377)

Skin Squamous Cell Carcinoma

pembrolizumab

immunotherapy

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

~95 mi. (Avignon, France, +226 more cities)

Institut Sainte Catherine ( Site 0447)

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

~95 mi. (Avignon, France, +207 more cities)

Institut Sainte Catherine ( Site 0916)

ER Positive, +1 more biomarker

Breast Invasive Ductal Carcinoma

cyclophosphamide, +6 more drugs

chemotherapy, +3 more types

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

~95 mi. (Avignon, France, +159 more cities)

Institut Sainte Catherine ( Site 0454)

Superficial Bladder Urothelial Carcinoma

cisplatin, +2 more drugs

chemotherapy, +1 more type

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

~95 mi. (Avignon, France, +131 more cities)

Institut du Cancer Avignon-Provence ( Site 1103)

HER2 Negative

Adenocarcinoma of the Gastroesophageal Junction, +2 more conditions

CAPOX regimen, +3 more drugs

chemotherapy, +2 more types

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

~95 mi. (Avignon, France, +150 more cities)

Institut Sainte Catherine ( Site 0352)

Head and Neck Squamous Cell Carcinoma

cisplatin, +2 more drugs

chemotherapy, +2 more types

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

~95 mi. (Avignon, France, +126 more cities)

Institut Sainte Catherine ( Site 0228)

Adenocarcinoma of the Gastroesophageal Junction, +1 more condition

FOLFOX regimen, +3 more drugs

chemotherapy, +2 more types

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

~95 mi. (Avignon, France, +92 more cities)

Institut Sainte Catherine ( Site 0121)

Bladder Urothelial Carcinoma

chemotherapy, +2 more drugs

chemotherapy, +2 more types